Phase 4 Pancreatitis Trial, Recruiting NCT06468709 Sponsor: Ruijin Hospital Condition: Pancreatitis
Back to Pancreatitis

Phase 4 Pancreatitis Trial, Recruiting

NCT06468709
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older (any gender)
  • You have been diagnosed with Type 1 Autoimmune Pancreatitis (a condition where the immune system attacks the pancreas) and are considered at high risk of it coming back, based on specific blood test results or the way the disease affects your body (confirm with trial site)
  • You have symptoms related to your pancreas or other organs, such as yellowing of the skin, abdominal pain, or back pain — or you have no symptoms but doctors are concerned about serious organ damage developing
  • You are able and willing to take medication by mouth and follow all study procedures throughout the trial
  • You have signed a dated consent form agreeing to take part
  • If you are a woman who could become pregnant, you have been using contraception for at least one month before joining and agree to continue doing so throughout the study and for a specified period after it ends

Who may not be able to join:

  • You are currently pregnant or breastfeeding
  • You are unable or unwilling to sign the consent form
  • You have a history of mental illness
  • You have a known allergy to the treatment being studied
  • You have been diagnosed with cancer
  • You currently have an active infection such as hepatitis or tuberculosis
  • You have a serious, hard-to-control health condition such as severe heart failure or breathing failure
  • You have taken steroids or immune-suppressing medications for any other illness within the past 3 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Duowu Zou, Doctor, Ruijin Hospital

Phone: 18817554263

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Registry
ClinicalTrials.gov
Start date
20 June 2024
Est. completion
31 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Evaluation of the impact of monotherapy with glucocorticoids and glucocorticoid combined with MMF maintenance therapy on disease remission rate in high-risk type I AIP patients for recurrence within 3 years

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov